IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC
September 21, 2022
Ryan Allway September 21st, 2022 News, Top News POTOMAC, Md., September 21, 2022–(BUSINESS WIRE)–India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme low... Read more
Ryan Allway June 22nd, 2022 News, Top News June 22, 2022, 11:26 PM EDT POTOMAC, Md.–(BUSINESS WIRE)–India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces its financial results for Fiscal Year Ended March 31, 2022. Highlights for Fiscal 2022: IGC completed the first-in-human safety and tolerability... Read more
Ryan Allway June 21st, 2022 News, Top News BETHESDA, Md., June 21, 2022–(BUSINESS WIRE)–India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimer’s drug development candidate. Researchers at the Jawaharlal Nehru Centre for... Read more
Ryan Allway March 4th, 2022 Psychedelics, Top News VANCOUVER, British Columbia, March 04, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”), has entered into an agreement with the... Read more
SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer’s Disease
January 6, 2022
Ryan Allway January 6th, 2022 The clinical trial will be conducted at The Israeli Alzheimer’s Medical Center and will evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation TEL AVIV, Israel, Jan. 6, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC) (the “Company”), a clinical-stage pharmaceutical... Read more
Ryan Allway April 29th, 2021 Psychedelics VANCOUVER, British Columbia, April 29, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”), a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce that it has... Read more
